Clinical predominance of whole‐exome sequencing to evaluate microsatellite instability status

Abstract

AbstractThe microsatellite instability (MSI)/mismatch repair (MMR) status is one of the critical genomic biomarkers for predicting patient response to immune checkpoint inhibitors (ICIs). In this study, we aimed to investigate the concordance among the MSIsensor score obtained from whole‐exome sequencing (WES), which could be a futuristic clinical cancer sequencing method, using only tumor tissues, MSI‐PCR results, and immunohistochemistry (IHC) results to analyze various solid cancer types. We first endeavored to set the cut‐off value of MSIsensor to determine functional deficient mismatch repair (f‐dMMR) status. The MSI status of 1054 patients analyzed using WES was evaluated using MSIsensor. In addition, 87 of these patients were further analyzed using MSI‐PCR and MMR IHC to calculate the sensitivity and specificity of the MSIsensor cut‐off score. Our results showed that score 12.5 was an adequate cut‐off score equivalent to PCR‐confirmed MSS/MSI‐low and MSI‐high statuses, with sensitivity, specificity, and area under the curve values of 95.2%, 100%, and 0.998, respectively. Moreover, we identified false‐positive cases of tumors with high mutational burden with an MSIsensor score <12.5, and optional IHC examination could rescue these cases. In conclusion, the MSIsensor score obtained using WES with tumor tissue showed a high clinical validity, with a cut‐off value of 12.5 for f‐dMMR detection, in combination with optional IHC analysis for MMR. Our novel algorithm will provide insights into the development of ICIs for cancer treatment, particularly when WES becomes a more common cancer genomic test in the near future.